4月1日 - ** 药物开发商Janux Therapeutics JANX.O股价盘前上涨1.1%至14.05美元
** 该公司称，它已根据与百时美施贵宝BMY.N签订的全球许可协议 (link)，提名了一个候选开发药物，触发了3500万美元的里程碑付款
** 根据协议，Janux公司负责利用其平台，针对一种在多种癌症类型中表达的未公开的实体瘤抗原，进行实验性治疗的临床前开发。
** Janux 有资格获得额外的开发、监管和商业里程碑付款，以及全球产品销售的分级版税。
** 截至上次收盘，JANX年累计上涨0.7%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.